Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2020

12.04.2020 | Retinal Disorders

Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion

verfasst von: Yeo-Yang Koh, Chi-Chun Lai, Wei-Chi Wu, Yih-Shiou Hwang, Kuan-Jen Chen, Nan-Kai Wang, Tun-Lu Chen, Jerry Chien-Chieh Huang, Laura Liu, Ling Yeung

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate prognostic factors in young patients with central retinal vein occlusion (CRVO).

Methods

Retrospective case series. CRVO patients aged ≤ 50 and follow-up ≥ 6 months were enrolled. The best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline, 3 months, 6 months, and last visit were documented. Severity of retinopathy was graded by comparing to standard photos. Prognostic factors associated with visual outcome at 6 months were evaluated by multiple linear regression models.

Results

A total of 73 eyes from 69 patients with mean age 37.6 ± 8.5 were enrolled. Forty-seven (68%) patients were male. The mean follow-up duration was 25.9 ± 23.0 months. LogMAR BCVA improved from 0.979 ± 0.785 at baseline to 0.594 ± 0.748 at the 6 months (p < 0.001) and CRT improved from 475 ± 222 μm to 299 ± 104 μm (p < 0.001). Forty-eight (66%) eyes required anti-vascular endothelial growth factor (anti-VEGF) treatment. The mean number of injections was 2.25 ± 1.41 in the first 6 months and 75% of eyes received ≦ 3 injections during the clinical course. The baseline BCVA (coefficient 0.518, p < 0.001), grade of retinal hemorrhage (coefficient 0.230, p = 0.006), grade of retinal venous engorgement (coefficient 0.238, p = 0.011), grade of optic disc edema (coefficient − 0.226, p = 0.005), and diabetes mellitus (coefficient 0.264, p = 0.047) were the independent factors associated with visual outcome at 6 months.

Conclusions

Baseline clinical features are useful for the prediction of visual outcome at 6 months in young CRVO patients.
Literatur
1.
Zurück zum Zitat Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al (2010) International eye disease C: the prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319CrossRef Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al (2010) International eye disease C: the prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319CrossRef
2.
Zurück zum Zitat Kohner EM, Cappin JM (1974) Do medical conditions have an influence on central retinal vein occlusions? Proc R Soc Med 67:1052–1054PubMedPubMedCentral Kohner EM, Cappin JM (1974) Do medical conditions have an influence on central retinal vein occlusions? Proc R Soc Med 67:1052–1054PubMedPubMedCentral
3.
Zurück zum Zitat Walters RF, Spalton DJ (1990) Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Ophthalmol 74:30–35CrossRef Walters RF, Spalton DJ (1990) Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Ophthalmol 74:30–35CrossRef
4.
Zurück zum Zitat Hayreh SS, Podhajsky PA, Zimmerman MB (2011) Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 118:119–133CrossRef Hayreh SS, Podhajsky PA, Zimmerman MB (2011) Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 118:119–133CrossRef
5.
Zurück zum Zitat Lindsell LB, Lai MM, Fine HF (2015) Current concepts in managing retinal vein occlusion in young patients. Ophthalmic Surg Lasers Imaging Retina 46:695–701CrossRef Lindsell LB, Lai MM, Fine HF (2015) Current concepts in managing retinal vein occlusion in young patients. Ophthalmic Surg Lasers Imaging Retina 46:695–701CrossRef
6.
Zurück zum Zitat Rothman AL, Thomas AS, Khan K, Fekrat S (2019) Central retinal vein occlusion in young individuals: a comparison of risk factors and clinical outcomes. Retina 39:1917–1924CrossRef Rothman AL, Thomas AS, Khan K, Fekrat S (2019) Central retinal vein occlusion in young individuals: a comparison of risk factors and clinical outcomes. Retina 39:1917–1924CrossRef
7.
Zurück zum Zitat Kuo JZ, Lai CC, Ong FS, Shih CP, Yeung L, Chen TL et al (2010) Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality. Retina 30:479–484CrossRef Kuo JZ, Lai CC, Ong FS, Shih CP, Yeung L, Chen TL et al (2010) Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality. Retina 30:479–484CrossRef
8.
Zurück zum Zitat Recchia FM, Carvalho-Recchia CA, Hassan TS (2004) Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol 122:317–321CrossRef Recchia FM, Carvalho-Recchia CA, Hassan TS (2004) Clinical course of younger patients with central retinal vein occlusion. Arch Ophthalmol 122:317–321CrossRef
9.
Zurück zum Zitat Wittstrom E (2017) Central retinal vein occlusion in younger Swedish adults: case reports and review of the literature open. Ophthalmol J 11:89–102 Wittstrom E (2017) Central retinal vein occlusion in younger Swedish adults: case reports and review of the literature open. Ophthalmol J 11:89–102
10.
Zurück zum Zitat Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133CrossRef Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133CrossRef
11.
Zurück zum Zitat Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G et al (2013) VEGF trap-eye for macular edema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97:278–284CrossRef Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G et al (2013) VEGF trap-eye for macular edema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97:278–284CrossRef
12.
Zurück zum Zitat Bressler SB, Edwards AR, Andreoli CM, Edwards PA, Glassman AR, Jaffe GJ et al (2015) Reproducibility of Optovue RTVue optical coherence tomography retinal thickness measurements and conversion to equivalent Zeiss stratus metrics in diabetic macular edema. Transl Vis Sci Technol 4:5CrossRef Bressler SB, Edwards AR, Andreoli CM, Edwards PA, Glassman AR, Jaffe GJ et al (2015) Reproducibility of Optovue RTVue optical coherence tomography retinal thickness measurements and conversion to equivalent Zeiss stratus metrics in diabetic macular edema. Transl Vis Sci Technol 4:5CrossRef
13.
Zurück zum Zitat Hayreh SS, Zimmerman MB (2015) Fundus changes in central retinal vein occlusion. Retina 35:29–42CrossRef Hayreh SS, Zimmerman MB (2015) Fundus changes in central retinal vein occlusion. Retina 35:29–42CrossRef
14.
Zurück zum Zitat Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121:202–208CrossRef Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121:202–208CrossRef
15.
Zurück zum Zitat Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRef Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRef
16.
Zurück zum Zitat Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG (2013) Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 120:795–802CrossRef Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG (2013) Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 120:795–802CrossRef
17.
Zurück zum Zitat The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491CrossRef The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491CrossRef
18.
Zurück zum Zitat Muraoka Y, Uji A, Tsujikawa A, Murakami T, Ooto S, Suzuma K et al (2017) Association between retinal hemorrhagic patterns and perfusion status in eyes with acute central retinal vein occlusion. Retina 37:500–508CrossRef Muraoka Y, Uji A, Tsujikawa A, Murakami T, Ooto S, Suzuma K et al (2017) Association between retinal hemorrhagic patterns and perfusion status in eyes with acute central retinal vein occlusion. Retina 37:500–508CrossRef
19.
Zurück zum Zitat Yasuda S, Kachi S, Kondo M, Ueno S, Kaneko H, Terasaki H (2015) Significant correlation between retinal venous tortuosity and aqueous vascular endothelial growth factor concentration in eyes with central retinal vein occlusion. PLoS One 10:e0134267CrossRef Yasuda S, Kachi S, Kondo M, Ueno S, Kaneko H, Terasaki H (2015) Significant correlation between retinal venous tortuosity and aqueous vascular endothelial growth factor concentration in eyes with central retinal vein occlusion. PLoS One 10:e0134267CrossRef
20.
21.
Zurück zum Zitat Lonn LI, Hoyt WF (1966) Papillophlebitis: a cause of protracted yet benign optic disc edema. Eye Ear Nose Throat Mon 45:62PubMed Lonn LI, Hoyt WF (1966) Papillophlebitis: a cause of protracted yet benign optic disc edema. Eye Ear Nose Throat Mon 45:62PubMed
22.
Zurück zum Zitat Fong AC, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L et al (1992) Central retinal vein occlusion in young adults (papillophlebitis). Retina 12:3–11CrossRef Fong AC, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L et al (1992) Central retinal vein occlusion in young adults (papillophlebitis). Retina 12:3–11CrossRef
23.
Zurück zum Zitat Beaumont PE, Kang HK (2000) Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol 118:1357–1363CrossRef Beaumont PE, Kang HK (2000) Pattern of vascular nonperfusion in retinal venous occlusions occurring within the optic nerve with and without optic nerve head swelling. Arch Ophthalmol 118:1357–1363CrossRef
24.
Zurück zum Zitat Hayreh SS, van Heuven WA, Hayreh MS (1978) Experimental retinal vascular occlusion. I Pathogenesis of central retinal vein occlusion. Arch Ophthalmol 96:311–323CrossRef Hayreh SS, van Heuven WA, Hayreh MS (1978) Experimental retinal vascular occlusion. I Pathogenesis of central retinal vein occlusion. Arch Ophthalmol 96:311–323CrossRef
25.
Zurück zum Zitat Hayreh SS (1965) Occlusion of the central retinal vessels. Br J Ophthalmol 49:626–645CrossRef Hayreh SS (1965) Occlusion of the central retinal vessels. Br J Ophthalmol 49:626–645CrossRef
26.
Zurück zum Zitat Santiago JG, Walia S, Sun JK, Cavallerano JD, Haddad ZA, Aiello LP et al (2014) Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion. Eye (London, England) 28:259–268CrossRef Santiago JG, Walia S, Sun JK, Cavallerano JD, Haddad ZA, Aiello LP et al (2014) Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion. Eye (London, England) 28:259–268CrossRef
27.
Zurück zum Zitat Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y (2017) Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol 11:441–447CrossRef Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y (2017) Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol 11:441–447CrossRef
28.
Zurück zum Zitat Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO (2010) Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost 103:299–305CrossRef Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO (2010) Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost 103:299–305CrossRef
30.
Zurück zum Zitat Kuhli-Hattenbach C, Hellstern P, Nägler DK, Kohnen T, Hattenbach LO (2017) Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. Ophthalmic Genet 38:413–417CrossRef Kuhli-Hattenbach C, Hellstern P, Nägler DK, Kohnen T, Hattenbach LO (2017) Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. Ophthalmic Genet 38:413–417CrossRef
31.
Zurück zum Zitat Liu Q, Lahey JM, Karlen R, Stewart JM (2018) Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Retina 38:1175–1179CrossRef Liu Q, Lahey JM, Karlen R, Stewart JM (2018) Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Retina 38:1175–1179CrossRef
32.
Zurück zum Zitat Larsen M, Waldstein SM, Boscia F, Gerding H, Mones J, Tadayoni R et al (2016) Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123:1101–1111CrossRef Larsen M, Waldstein SM, Boscia F, Gerding H, Mones J, Tadayoni R et al (2016) Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123:1101–1111CrossRef
33.
Zurück zum Zitat Blanc J, Deschasse C, Kodjikian L, Dot C, Bron AM, Creuzot-Garcher C (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol 256:1441–1448CrossRef Blanc J, Deschasse C, Kodjikian L, Dot C, Bron AM, Creuzot-Garcher C (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol 256:1441–1448CrossRef
34.
Zurück zum Zitat Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R et al (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253:2095–2102CrossRef Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R et al (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253:2095–2102CrossRef
35.
Zurück zum Zitat Ding X, Li J, Hu X, Yu S, Pan J, Tang S (2011) Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 31:838–845CrossRef Ding X, Li J, Hu X, Yu S, Pan J, Tang S (2011) Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 31:838–845CrossRef
36.
Zurück zum Zitat Ozkok A, Saleh OA, Sigford DK, Heroman JW, Schaal S (2015) THE OMAR STUDY: comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina 35:1393–1400CrossRef Ozkok A, Saleh OA, Sigford DK, Heroman JW, Schaal S (2015) THE OMAR STUDY: comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina 35:1393–1400CrossRef
37.
Zurück zum Zitat Evans K, Wishart PK, McGalliard JN (1993) Neovascular complications after central retinal vein occlusion. Eye (London, England) 7(Pt 4):520–524CrossRef Evans K, Wishart PK, McGalliard JN (1993) Neovascular complications after central retinal vein occlusion. Eye (London, England) 7(Pt 4):520–524CrossRef
38.
Zurück zum Zitat Rong AJ, Swaminathan SS, Vanner EA, Parrish RK 2nd (2019) Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol 204:62–69CrossRef Rong AJ, Swaminathan SS, Vanner EA, Parrish RK 2nd (2019) Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol 204:62–69CrossRef
39.
Zurück zum Zitat Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL et al (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina 34:1728–1735CrossRef Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL et al (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina 34:1728–1735CrossRef
40.
Zurück zum Zitat Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ et al (2011) SCORE study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology 118:1364–1372CrossRef Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ et al (2011) SCORE study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology 118:1364–1372CrossRef
41.
Zurück zum Zitat Ryu CL, Elfersy A, Desai U, Hessburg T, Edwards P, Gao H (2014) The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol 2014:317694CrossRef Ryu CL, Elfersy A, Desai U, Hessburg T, Edwards P, Gao H (2014) The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol 2014:317694CrossRef
Metadaten
Titel
Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion
verfasst von
Yeo-Yang Koh
Chi-Chun Lai
Wei-Chi Wu
Yih-Shiou Hwang
Kuan-Jen Chen
Nan-Kai Wang
Tun-Lu Chen
Jerry Chien-Chieh Huang
Laura Liu
Ling Yeung
Publikationsdatum
12.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 7/2020
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-020-04679-8

Weitere Artikel der Ausgabe 7/2020

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2020 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.